iguratimod has been researched along with Pneumonia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, D; Liang, Y; Qu, Z; Shao, S; Xu, Y; Yin, S; Zhang, Y; Zhou, D | 1 |
| Cheng, Y; Huang, C; Mu, B; Zhao, L; Zhou, R | 1 |
2 other study(ies) available for iguratimod and Pneumonia
| Article | Year |
|---|---|
Iguratimod decreases bleomycin-induced pulmonary fibrosis in association with inhibition of TNF-α in mice.
Topics: A549 Cells; Actins; Animals; Bleomycin; Cadherins; Chromones; Collagen; Disease Models, Animal; Epithelial-Mesenchymal Transition; Humans; Matrix Metalloproteinase 2; Mice; NF-kappa B; Pneumonia; Pulmonary Fibrosis; Signal Transduction; Sulfonamides; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Vimentin | 2021 |
Iguratimod ameliorates bleomycin-induced alveolar inflammation and pulmonary fibrosis in mice by suppressing expression of matrix metalloproteinase-9.
Topics: Airway Remodeling; Animals; Anti-Inflammatory Agents; Bleomycin; Chromones; Collagen; Cytokines; Disease Models, Animal; Inflammation Mediators; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice, Inbred C57BL; Pneumonia; Pulmonary Alveoli; Pulmonary Fibrosis; Sulfonamides | 2019 |